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Summary Cells from rat carcinoma cell lines PROb (giving progressive tumours) and REGb (giving regres-
sive tumours) have cell surface receptors which bind specifically rat plasminogen and plasmin. Affinity for Pg
was found to be higher in PROb (Kd = 0-7M) than in REGb cells (Kd = 5.10-7M) but with a concomitant
decrease in the number of binding sites, 0.9 x 106/cell (range from 0.6 to 1.2 x 106) in PROb vs 3.6 x 106/cell
(range 1.2 to 6 x 106 ) in REGb cells. The number and the affinity of binding sites varied in an opposite way
in PROb and REGb cells. The difference in affinity parameters was unrelated to the degree of invasiveness of
tumour cells in syngenetic rats.
Bound plasmin retained its enzymatic activity, which indicates that its binding does not involve the catalytic
active site.
In cell solubilisates plasminogen receptor appeared as one major band situated in the area of 50-60 kDa.
It is now established that proteinases are involved in the
invasive process of tumour cells (Mullins & Rohrlich, 1983;
Saksela & Rifkin, 1988). Malignant cells may produce plas-
minogen activators (PAs) of either the urokinase or tissue
type or both. These PAs are able to convert plasminogen into
plasmin which is a potent protease (Dano et al., 1985).
Carcinoma cells can use plasmin to activate latent type IV
collagenase (Salo et al., 1982). Plasmin can also take a direct
part in the degradation of components of the basement
membrane and the surrounding connective tissue, facilitating
the migration of tumour cells (Ossowski, 1988).
By using immunofluorescence with antisera against com-
ponents of the plasmin system on sections of both human
colon and breast adenocarcinomas, Burtin et al. (1985; 1987)
showed that these carcinoma cells had plasminogen or plas-
min at their surface, and made the hypothesis that these
molecules were bound specifically. Subsequently, Burtin and
Fondaneche (1988) demonstrated that cells from human
tumour cell line SW 1116 have specific binding sites for
plasmin and plasminogen. These binding sites are the same
for the proenzyme and the enzyme, but they exhibit a much
higher affinity for plasmin than for plasminogen. Recently,
analogous results have been obtained in our laboratory on
the human MCF7 breast carcinoma cell line (Correc et al.,
1990).
In order to extend this research to animal, we investigated
whether rat colonic tumour cells have binding sites for plas-
minogen. We tested an in vitro system with two sublines of
rat colon cancer cells forming either progressive tumours
(PROb cells) or regressive tumours (REGb cells).
Materials and methods
Cells
Normal colon was excised from adult healthy WAG rats and
carefully washed in 0.9% NaCl. The crypt cells were
obtained according to the method of M. Laburthe (personal
communication). Briefly, the washed colon was turned inside
out so that the crypt cells were exposed, and washed carefully
several times with 0.9% NaCl. Then the epithelial cells were
dissociated by using a hypertonic solution containing 1.4%
NaCl and 2.5 mM EDTA, collected after gentle centrifuga-
tion and resuspended in PBS (phosphate buffered saline).
The tumour cell line DHD/K12 was obtained from a
transplantable colon carcinoma induced by 1,2 dimethyl-
hydrazine in BDIX rats (Martin et al., 1983). Two sublines,
named respectively DHD/K12/TR and DHD/K12/TS were
selected according to their susceptibility to trypsin-mediated
detachment from a plastic surface. Clones derived from these
sublines and called DHD/K12/TRb and DHD/K12/TSb were
used in this study. When injected into syngenic rats DHD/
K12TRb cells, the most resistant to trypsin-mediated detach-
ment, gave rise to progressive tumours in most ofthe animals
(hence their name of PROb), whereas DHD/K12/TSb cells
(named REGb), easily detached by trypsin, gave no tumours
or produced tumours which regressed spontaneously in a few
weeks (Martin et al., 1983). These cells were grown in Ham's
FIO medium supplemented with 10% foetal calf serum and
1% of antibiotic solution containing 10,000 IU ml-' penicil-
lin and 10,000 UG ml- streptomycin.
Preparation ofratplasminogen andplasmin
Blood from 200 male adult WAG rats was withdrawn in the
presence of heparin (Choay, Paris, France) by intracardiac
puncture. The blood samples collected were immediately
pooled with an anticoagulant solution (0.017 M citric acid,
0.087 M trisodic citrate, 0.14 M glucose, 0.02 M NaH2PO4),
supplemented with 1200 TIU aprotinin and lOjsM benza-
midine at pH 7.0. Plasminogen (Pg) was prepared by affinity
chromatography on lysine-sepharose and further purified by
anion exchange chromatography as previously described
(Bertrand et al., 1986). Pg was then labelled with 1251 (Amer-
sham, Les Ulis, France) using the iodogen technique (Fraker
& Speck, 1978). A specific activity of 4-8yCi g-' protein
(148-296 Kbq) was routinely obtained.
Non radiolabelled Pg could be activated by addition of
human urokinase (Choay) (5000 IU for 10l g of Pg) after
30 min incubation at 37°C. Ten pg radiolabelled Pg were
transformed into plasmin (Pli) by the addition of 10,000 IU
human urokinase. Completion of this activation was checked
by PAGE followed by autoradiography. Gel electrophoresis
was performed in 10% polyacrylamide gel in the presence of
0.1% sodium-dodecyl-sulphate (SDS) and 0.2 mM P mer-
captoethanol. Gels were stained by Coomassie Blue, or dried
and covered with Hyper films MP (Amersham). The activa-
tion of non radiolabelled Pg appeared as complete whereas
the activation of radiolabelled Pg into Pli by human
urokinase was incomplete (from about 50 to 80%).
Correspondence: P. Burtin.
Received 23 July 1991; and in revised form 11 March 1992.
Br. J. Cancer (1992), 66, 51-56 'PI Macmillan Press Ltd., 199252 M. DURLIAT et al.
Binding experiments
Cells from PROb or REGb clones were detached from tissue
culture flasks by a mixture of trypsin and EDTA, then
suspended in 10ml Ham's F1O medium supplemented with
10% foetal calf serum, centrifuged for 5 min at 1,000 r.p.m.
and again suspended in the same medium. Cells were seeded
in individual plastic wells (Nunclon 1/67008) (6 x 103 per
well) and grown in Ham's F 10 medium for up to 3 days
without attaining confluence. Tumour cells were washed
three times in PBS before a treatment with either an acidic
buffer (glycine 0.05 M, NaCl 0.15 M at pH 3) 10 min at 37°C,
or with a solution of 50 nM human plasmin (Kabi, Les Ulis,
France), 30 min at 37°C, or with successively 10 min of acidic
treatment followed by 30 min human plasmin proteolysis.
Camacho et al. (1989) have shown that limited proteolysis of
human tumour cells increased their plasmin-binding ability
by increasing the number of binding sites. Comparable bin-
ding was obtained with cells treated with acidic buffer, with
cells treated with human plasmin, or with cells submitted to
both. Routinely, experiments were performed with human
plasmin alone. Cells were then incubated for h at 4°C with
increasing concentrations of radiolabelled rat Pg. Specific
binding was determined as the difference between total bin-
ding and binding observed in the presence of 21M non-
radiolabelled Pg. Inhibition experiments with Pli were per-
formed in the presence of 900 KIU aprotinin (Trasylol,
Sigma) in order to prevent autodegradation of Pli incubated
with the tumour cells. Inhibition experiments were made
using standard concentrations of 1251 Pg (3 nM) with increas-
ing amounts of cold plasminogen or plasmin, or with
unrelated proteins at high concentrations such as 3pM trans-
ferrin, 4,sM ovalbumin or with 10, 50 or 100 mM lysine (all
from Sigma, Saint-Louis, USA). Finally the cells were
washed three times with PBS and the bound ligand was
solubilised with 1 N NaOH. The radioactivity was counted in
a Wallac LKB spectrometer.
In some experiments after Pg binding at 4°C, the cells were
incubated at 37°C for 20 min with a glycine buffer 5 mM
pH 3, containing 0.15 M NaCl. The supernatants were
studied by PAGE under reducing or non-reducing conditions
followed by autoradiography.
Analogous experiments were carried out on intestinal crypt
cells of control rats. Inhibition experiments were made using
standard concentration of 1251 Pg (1 nM) with increasing
amounts of cold Pg, cold Pli or with high concentrations of
unrelated proteins, such as 3tiM transferrin or with 10, 50 mM
lysine. Some experiments of binding were also performed
with 1251 human plasmin and inhibitions were made with cold
human plasmin.
Scatchard plots were established from inhibition curves,
using a programme that permitted calculation of the binding
parameters, dissociation constant and the number of binding
sites.
The enzymatic activity of cell-bound Pg or Pli was also
studied. Tumour cells were seeded in 16-well Costar plates
then incubated 30 min at 37°C with 100 nM human uPA, or
200 nM rat Pg alone, or with 20, 50, 100, 200 nM rat plasmin.
after three washings, a synthetic ligand, H-D-valyl-L-Leucyl-
L-lysine-7 amino-4 methyl coumarin (Bachem, Budendorf,
Switzerland) at a concentration of 5 jig ml- l in PBS was
added. The incubation lasted 30 min at 37°C. The fluo-
rescence due to the release of aminomethyl-coumarin from
this peptide allowed to estimate enzymatic activity. The
release of fluorochrome was measured in a Jobin and Yvon
spectrofluorometer (Paris, France) (A excitation, 365 nm; A
emission, 450 nm).
Solubilisates
When tumour cells PROb and REGb were near confluence in
175 cm2 Falcon flasks, they were washed three times with
PBS, and gently scraped with 10 ml PBS containing 200 KIU
aprotinin. After centrifugation 5 min at 1200 r.p.m., the
pellet was incubated 20 minat room temperature in 1ml PBS
buffer containing 1% SDS + 25% glycerol and a mixture of
antiproteases (100 KIU aprotinin, 0.1 mM DFP, 1OgM Pep-
statin, 1 gLM E64 and 5 mM EDTA, all obtained from Sigma).
The solubilisates were centrifugated at 190,000 g, 1 h at 4°C.
The supernatants were collected and the protein content was
determined using the BCA reagent (Biorad, Richmond, CA).
An amount of 500-700ttgml-' was routinely obtained with
both PROb and REGb cells.
Dot blot technique and SDS-PAGE
These solubilisates were tested for their Pg binding activity in
dot blots and their contents analysed in electrophoresis
followed by transfer and autoradiography as already des-
cribed (Burtin & Fondaneche, 1990).
Rows of dots were incubated 1 h at 4°C with 1 nM
radiolabelled rat Pg in incubation buffer. In parallel
experiments radiolabelled Pg was mixed with 1 llM cold Pg or
an unrelated cold protein such as 2gM transferrin or 2gM
ovalbumin. Other samples were run in 10% polyacrylamide
gels containing 0.1% SDS without previous boiling nor addi-
tion of 3-mercaptoethanol. However, some samples were
mixed with 0.2 M 1P mercaptoethanol and boiled for 5 min.
Proteins were then electrically transferred to nitrocellulose
sheets. These sheets were incubated 1 h at 4°C with 1 nM
radiolabelled rat Pg alone or mixed with an excess of cold
proteins either 1 ftM of cold Pg or 2tLM of transferrin then
after washings and drying covered with hyperfilms MP
(Amersham). Exposure time lasted 18 h at - 80°C.
Results
Existence ofplasminogen binding sites on PROb and REGb
cells
Radiolabelled rat Pg was weakly bound on colon cells from
healthy control rats, but this fixation was not inhibited by
cold Pg or Pli (Table I). Radiolabelled Pg was bound
specifically by PROb and REGb cells. This binding was
saturable (Figure 1) and time-dependent; the maximum of Pg
binding was obtained after 1 h of incubation (for instance on
Table I Inhibition of radiolabelled rat Pg binding on normal colon
cells
Coldproteins % inhibition ofrat Pg* binding
RatPglOOnM 11%
Rat Pg 500nM 13%
Rat Pg I gM 6%
Rat Pg 2jM 8%
Rat Pli 50 nM 5%
Rat Pli 100 nM 5%
Transferrin 3tLM 11%
Lysine 10mM 42%
Lysine 50mM 65%
Normal colon cells were incubated for I h at 4°C with radiolabelled
plasminogen (1 nM) alone or mixed with excess of cold proteins.
Table II Inhibition of Pg binding on tumour cells by cold proteins
Coldproteins PROb cells REGb cells
Plasminogen 200 nM 50% 15-20%
Plasminogen 1 JAM 60-70% 50%
Plasminogen 2 JAM 75-90% 70-80%
Plasmin 50-100 nM 50% 50%
Plasmin 1JLM 70-85% 70-85%
Ovalbumin 4gM 0% 0%
Transferrin 3JAM 0-10% 0- 10%
Lysine 50mM 80-90% 80-90%
Lysine 100mM 90-98% 90-98%
DHD-K12 PROb or REGb cells were incubated for 1h at 4°C with
radiolabelled plasminogen (3 nM) alone or mixed with excess of cold
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Figure 1 Curves of specific binding of rat plasminogen on
tumour cells PROb and REGb. Cells were incubated for I h at
4C with increasing amounts of radiolabelled plasminogen either
alone or with an excess of cold Pg. Specific binding was deter-
mined as the difference between total binding and binding
observed in the presence of excess of cold Pg. REGb; A
PROb.
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Figure 2 Curve for plasminogen-binding inhibition. PROb cells
were incubated for 1 h at 4°C with radiolabelled Pg (3 nM) and
various amounts of cold plasminogen (50 nM-2 PM).
PROb cells, we found a binding of 7775 d.p.m. after 15 min;
9824 d.p.m. after 30 min; 13202 d.p.m. after 1 h; 12243 d.p.m.
after 2 h; 13105 d.p.m. after 3 h). A strong inhibition was
observed with cold plasminogen (Figure 2) and with cold
plasmin, but not with high amounts of unrelated cold pro-
teins (Table II). A strong inhibition was also noted with
lysine (50 or 100 mM), proving that Pg interacts with its
receptor by the intermediate of lysine-binding sites. Basically,
both sublines were able to bind radiolabelled Pg specifically
but differences were observed in binding parameters.
In some experiments, the bound radiolabelled Pg was
eluted from PROb or REGb cells by using a glycine buffer
(pH 3). The major part (from 70 to 90%) of the bound
radioactivity could be solubilised, that shows that most of
the ligand was not internalised. These eluates were studied by
PAGE under reducing conditions followed by autoradio-
graphy. A unique Pg band at 92 kD was observed (Figure 3).
Figure 3 Autoradiographs after polyacrylamide gel electro-
phoresis of rat native ligand, rat plasminogen activated by human
uPA and cell eluates. Electrophoreses were performed in 10%
PAGE in presence of 0.2 mm P mercaptoethanol for I h 30 at
150V. Then gels were dried and covered with Hyper film MP.
Exposure lasted 2-48 h at - 80C. Lane 1, rat radiolabelled
plasminogen; lane 2, radiolabelled plasmin obtained after incuba-
tion ofPg with human uPA. Lanes 3 and 4: PROb or REGb cells
were incubated with 20 nM radiolabelled Pg 1 h at 4°C. After
washings, cell-bound radioactivity was counted and then eluted
10 min at 37'C with glycine buffer pH 3. Lane 3, eluate of REGb
cells; lane 4, eluate of PROb cells.
Table III Enzymatic activity of PROb cell-bound Pg or Pli
Product(s) added to Fluorescence intensity Fluorescence intensity
cells Gain: 100 x Gain: 10 x
Control: peptide alone 0.115
Human uPA 100 nM 0.076
Rat Pg 200 nM 0.120
Human uPA 100 nM + 0.347
rat Pg 20 nM
Human uPA 100 nM+ > 2 0.365
rat Pg 200 nM
Rat Pli 20 nM 0.298
Rat Pli 50 nM >2 0.190
Rat Pli 100 nM >2 0.220
Rat Pli 200 nM >2 0.325
Rat Pli 20 nM + 0.108
aprotinin
Rat Pli 100 nm + 0.152
aprotinin
Release of fluorochrome was measured in a Jobin and Yvon
spectrofluorometer (A excitation: 365 nm; A emission: 450 nm).54 M. DURLIAT et al.
The fixation of radiolabelled plasmin on DHD/K12 cells
was not studied since it was not possible to activate rat
radiolabelled Pg completely with high amounts of human
uPA used either soluble or immobilised on CNBR-sepharose
column. In fact, we obtained a mixture containing both Pg
and plasmin. However experiments with cold plasmin showed
that the enzyme inhibited the fixation of labelled Pg on
tumour cells at lower doses than the proenzyme. An inhibi-
tion of about 50% was obtained with 50-100 nM cold plas-
min (Table II), whereas 200 nm cold Pg was needed to obtain
similar results with PROb cells, and 1ItM cold Pg with REGb
cells.
The enzymatic activity of cell-bound Pg or Pli on
chromogenic substrate was estimated (Table III). Similar
results were obtained with PROb or REGb cells. Fluo-
rescence intensity was very weak when Pg alone was
incubated with tumour cells. It was two to ten fold higher
when cells were incubated with increasing doses of plasmin.
This activity was always abolished in the presence of
aprotinin. Thus, enzymatic activity of plasmin was retained
after incubation with the tumour cells and the catalytic active
site appeared not to be involved in the binding to cells.
Some experiments were performed on whole cells seeded
on glass coverslips. After incubation with a 0.25% trypsin
solution, although some cells were detached, the preparations
were incubated with biotinylated Pg (usually 12jg ml' in
PBS) for 30 min at 4°C as already described (Correc et al.,
1992). They were reacted with fluoresceinated streptavidin.
The ability of tumour cells to bind Pg was not altered since
fluorescent patterns were observed on the outlines of remain-
ing cells and on the extracellular matrix, as observed on
untraited cells (data not shown).
Characteristics ofbinding sites on PROb or REGb cells
Radioligand displacement assays by cold Pg performed on
PROb cells gave the following results: 65%-80% inhibition
in the presence of 1 tLM cold Pg vs 0-10% in the presence of
PBS or high amounts of cold ovalbumin or human transfer-
rin. Pg binding was inhibited 50% by 200 nM cold Pg.
Using the data from ten inhibition experiments, the dis-
sociation constant of Pg was calculated according to Scat-
chard's method. The Kd was about 1.0 x 10-7M. The
number of binding sites was 0.9 x 106 per cell (range from
0.6 to 1.2 x 106 per cell).
Analogous experiments were performed with REGb cells
(Table II). Pg binding was inhibited 50% by 1 flM cold Pg.
Using the data from ten inhibition experiments, the dissocia-
tion constant was about 5 x 10-7 M. The number of binding
sites was about 3.6 x 106 per cell (range from 1.2 to 6.106 by
cell). The Figure 4 shows the comparison of the two Scat-
chard plots obtained respectively with PROb and REGb
cells.
0.006
Dot blots
Ability of solubilisates to bind radiolabelled rat Pg
specifically was determined by the counting of dot blots. Five
replicates were made for each experiment. Using the data
from six different experiments, it appeared that the fixation
of radiolabelled Pg was inhibited by 50-70% on PROb and
by 60-80% on REGb solubilisates with 1 gLM cold rat Pg.
This inhibition was dose-dependent since for instance with
REGb solubilisates, it was only 50% with 700 nM cold Pg
and 40% with 500 nM cold Pg. The fixation of rat Pg was not
inhibited with 2 lAM transferrin or ovalbumin. However, in
some experiments transferrin showed minor inhibition which
was subtracted from that given by cold rat Pg in order to
calculate specific inhibition.
PAGE analysis ofSDS solubilisates
Autoradiograms obtained after incubation of nitrocellulose
sheets with radiolabelled rat Pg showed one major band in
the 50-60 kD area (Figure 5). In some cases two other
fainter bands were also visible in the 30 kD area. After
incubation with radiolabelled Pg mixed with 1 laM cold Pg
(1000 fold excess of cold Pg) no band was visible. No inhibi-
tion was noted ifradiolabelled Pg was mixed with 2tIM (2000
fold excess) cold transferrin (Figure 5). Identical patterns
were always observed on both PROb and REGb
solubilisates. The patterns were the same if SDS solubilisates
were boiled or treated with P-mercaptoethanol or both, in
particular the band situated in the 50-60 kD area was still
visible.
Discussion
Our results demonstrate that the two PROb and REGb
cancer cell lines can bind rat Pg in a time-dependent, specific
and saturable manner as do several human tumour lines with
human Pg (Burtin & Fondaneche, 1988; Corre et al., 1990).
This study has been impeded by technical difficulties since rat
uPA is not available commercially. When we used human
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Figure 4 Comparison of Scatchard plots of p1
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Figure 5 Characterisation of plasminogen receptor obtained
from solubilisates of PROb cells. After electrophoresis on 10%
-^_ PAGE, 1 h 30 at 150 V, all samples were transferred on nitro-
cellulose sheets. These sheets were incubated 1 h at 4°C with
1.2 1.6 different proteins, washed, dried, and covered with Hyper film
MP. Exposure lasted 18 h at - 80°. Lane 1, incubation of sheet
with 1 nm radiolabelled rat Pg. Lane 2, incubation with a mixture
lasminogen-binding of 1 nM radiolabelled Pg and 1 JiM cold Pg. Lane 3, incubation
ells. with a mixture of I nM radiolabelled Pg and 2JiM human trans-
ferrin.
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uPA, the activation of rat Pg was complete except when this
Pg was radiolabelled with '25I. Thus, it has not been possible
to study the binding of radiolabelled rat plasmin. However,
inhibition experiments seem to show that the same molecules
bind Pg or Pli with an higher affinity for Pli since the 50%
inhibition concentration of Pg binding is significantly smaller
for Pli than for Pg. That agrees with the results obtained on
human carcinoma cells (Burtin & Fondaneche, 1988; Correc
et al., 1990). It was shown that the same receptors bound
human Pli and Pg but the amount needed to inhibit the
radiolabelled human Pg binding by 50% was significantly
lower for Pli than for Pg. Note that these human receptors
linked human Pg with a lower affinity than those detected for
rat Pg on PROb or REGb cells (50 fold lower for SW 1116
cells and 10 fold for MCF7 cells).
Another piece of evidence shows that Pli is bound by
PROb and REGb cells: the cells incubated with cold rat Pli
acquired protease activity. That indicates also that the
catalytic active site of Pli is not required for its binding to
cancer cells. Furthermore, the rat Pli used to inhibit the
binding of radiolabelled Pg was always supplemented with
aprotinin which blocks the Pli active site, but does not
prevent its competitive effect. Identical results have been
previously obtained with human carcinoma cells (Burtin &
Fondaneche, 1988; Correc et al., 1990) which suggested that
the Pli binding on these rat carcinoma cells was also due to a
specific receptor and not to protease-nexin like molecules.
It was not possible to study the receptor for urokinase on
PROb and REGb cells, since rat uPA is not available, and it
was reported that the receptor for uPA is species-specific
(Appella et al., 1987; Estreicher et al., 1989). However on
human carcinoma cell line SW 1116, Burtin & Fondaneche
(1990) have shown that receptors for Pli and for uPA are
distinct proteins, since a high amount of urokinase does not
inhibit the specific binding of plasmin. As we have shown a
strong interspecific reactivity between the receptors for Pli
and for Pg on human and rat carcinoma cells (Durliat et al.,
1991), it is likely that the two systems are homologous and
that rat Pg receptor is distinct from rat uPA receptor.
It is clear that Pg binding sites are surface molecules. Two
types of experiments support this conclusion. First, after
binding of radiolabelled Pg, acid elution leads to recovery of
70-90% of the bound ligand. Second, fluorescence experi-
ments showed the staining of the surface of whole tumour
cells. Note also that on several human tumour cells (SW 1116
and MCF7-MF), Correc et al. (1992) have evidenced images
with green fluorescence clearly visible as grains or contours at
the surface of these tumour cells. Moreover, Pg binding sites
are membrane molecules since dissolved by detergent, but not
by hypertonic saline buffer.
Pg binding sites of high capacity, of similar affinities and
with common recognition specificities are also reported to be
widely distributed on many human blood cells with Kd
values of 0.9-1.4 I1M (Miles & Plow, 1987), and on both
promyeloid leukaemic U 937 and diploid foetal lung GM
1380 fibroblast cell lines (Plow et al., 1986).
The functional role of these rat Pg binding sites has not
been unambiguously determined on tumour cells. It is likely
that these binding sites serve to focus high amounts of Pg on
the surface of certain cells which could also bind uPA.
Activation of bound Pg by uPA could proceed in a very
effective way, thus generating abundant proteolytic activity
for the degradation of pericellular substrates, facilitating the
migration of tumour cells. Considering the great difference in
malignancy of PROb and REGb cells, we were interested in
determining whether the binding sites for Pg and/or for Pli
exhibited identical or different characteristics in the two cell
sublines. In fact, a higher affinity ( x 5) for Pg has been
observed on PROb than on REGb cells, but with a parallel
decrease in the number of binding sites. It is possible that
low and high affinity Pg receptors are different forms of the
same molecule as postulated for the receptors of uPA (Est-
reicher et al., 1989). Thus no significant difference in the
specific binding of rat Pg on these two cell lines was detected
which might be related to their degree of malignancy.
Analyses of solubilisates obtained from both PROb and
REGb cells show that these samples contain specific binding
sites for radiolabelled rat Pg. In electrophoresis, these recep-
tors exhibited the same mobility than those detected for Pli
and Pg on human epithelial tumour cell lines (Burtin &
Fondaneche, 1990; Correc et al., 1990).
We think that the cell surface Pg binding protein detected
in experiments dealing with whole cells corresponds to that
found in cell solubilisates. We found only one Pg binding
band in Western blots performed with cell solubilisates. This
means that this band is similar to the cell surface molecule,
unless this latter molecule was denatured during solubilisa-
tion process. Other evidence is derived from experiments
performed on human MCF7 tumour cells (P. Correc, unpub-
lished results). The Pg receptor was studied by cross-linking
technique and solubilisation with SDS. For the complex
between Pg and receptor, a molecular weight of
140-150 kDa was obtained after polyacrylamide gel electro-
phoresis and autoradiography. This indicates a molecular
weight of 50-60 kDa for the receptor molecule. As the rat
and human receptors are very similar (Durliat et al., 1991),
we believe that the rat Pg receptor has indeed the same
molecular weight, similar to that obtained on blotting
experiments.
To conclude, this study is the first characterisation of
specific Pg binding sites on rat carcinoma cell lines.
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